TCS
ACAD icon

Texas Children's’s Acadia Pharmaceuticals ACAD Stock Holding History

Texas Children's’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-24,471
Closed -$657K – 4
2019
Q1 		$657K Sell
24,471
-34,075
-58% -$796K 0.8% 19
2018
Q4 		$947K Buy
+58,546
New +$1.14M 1.32% 10

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Texas Children's's ACAD Position: Q2 2019 in Review

Texas Children's sold out of Acadia Pharmaceuticals (ACAD) in Q2 2019, closing a stake of 24,471 shares — an estimated $657K sold.

Texas Children's first reported a position in ACAD in Q4 2018 and held it in 2 quarters. The position peaked at $947K in Q4 2018. 196 funds tracked by Wall St. Rank hold ACAD as of Q2 2019.

  • Texas Children's reported no remaining Acadia Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Texas Children's sold 24,471 Acadia Pharmaceuticals shares in Q2 2019, an estimated $657K.
  • Texas Children's first reported a position in Acadia Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Texas Children's's Acadia Pharmaceuticals position peaked at $947K in Q4 2018.
  • 196 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2019.

Based on Texas Children's's 13F filing for Q2 2019, filed 13 Aug 2019.